We have received a proposal from Pharmac involving  Idarucizumab (Praxbind) and Dabigatran (Pradaxa) resulting from a provisional agreement with Boehringer-Ingelheim that will have a serious impact on both pharmacy and wholesalers if we do not manage our stocks of all strengths closely.

Praxbind Inj will be listed in Section H for use in DHB Hospitals and price reductions for Pradaxa.

Pradaxa current schedule price is $148.00 but is reducing to $76.36 effective in the schedule from 1 September 2016.

We anticipate the price to wholesale will reduce effectively 12 August 2016, but at present we are not anticipating price support being provided, which will require us to manage stock down and potentially jeopardise the continuity of supply. Not our choice, just a basic business necessity.

We will update once we have further information, but this is notification of the impending price decrease.

Pre-warned it pre-armed – manage your stock accordingly.

About The Author